Phaseline

Companies › Biogen

Biogen: clinical trials, targets and expected readouts

12 active drug programs in 25 registered trials: 12 Phase 3, 7 Phase 1, 5 Phase 2, 1 Phase 4; Neurology, Other, Immunology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tofersen
SOD1 mRNA antisense inhibitor
SOD1Phase 4Amyotrophic Lateral Sclerosis; Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation; ALS (Amyotrophic Lateral Sclerosis)May 2027
Felzartamab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 3Antibody-mediated Rejection; Immunoglobulin A Nephropathy (IgAN); Primary Membranous Nephropathy; Graves' Disease …Dec 2026
Litifilimab (BIIB059)
C-type lectin domain family 4 member C inhibitor
CLEC4CPhase 3Lupus Erythematosus, Systemic; Subacute Cutaneous Lupus ErythematosusMar 2027
Peginterferon Beta-1A (BIIB017)
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Multiple Sclerosis, Relapsing-RemittingMay 2027
Nusinersen (BIIB058)
SMN2 pre-mRNA positive modulator
SMN2Phase 3Spinal Muscular Atrophy; Muscular Atrophy, SpinalSep 2027
Omaveloxolone (BIIB141)
Nuclear factor erythroid 2-related factor 2 activator
NFE2L2Phase 3Friedreich AtaxiaNov 2027
Salanersen (BIIB115)
SMN2 splicing modulator that increases production of functional SMN protein
SMN2Phase 3Spinal Muscular Atrophy; Muscular Atrophy, Spinal; Healthy VolunteerJun 2028
Diranersen
Antisense oligonucleotide targeting ATXN2 mRNA
ATXN2Phase 2Mild Cognitive Impairment Due to Alzheimer's DiseaseJun 2028
BIIB145–Phase 1Healthy VolunteerFeb 2027
BIIB144–Phase 1Healthy VolunteerJun 2028
BIIB147–Phase 1Amyotrophic Lateral SclerosisJan 2034
BIIB142–Phase 1Healthy Volunteer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07133828BIIB142Phase 1Healthy VolunteerOtherAug 2026
NCT06685757FelzartamabPhase 3Antibody-mediated RejectionOtherDec 2026
NCT07294144TofersenPhase 2ALS (Amyotrophic Lateral Sclerosis)NeurologyJan 2027
NCT07225517BIIB145Phase 1Healthy VolunteerOtherFeb 2027
NCT04961567Litifilimab (BIIB059)Phase 3Lupus Erythematosus, SystemicImmunologyMar 2027
NCT04895241Litifilimab (BIIB059)Phase 3Lupus Erythematosus, SystemicImmunologyMar 2027
NCT03958877Peginterferon Beta-1A (BIIB017)Phase 3Multiple Sclerosis, Relapsing-RemittingNeurologyMay 2027
NCT07223723TofersenPhase 4Amyotrophic Lateral SclerosisNeurologyMay 2027
NCT06935357FelzartamabPhase 3Immunoglobulin A Nephropathy (IgAN)GenitourinaryMay 2027
NCT04856982TofersenPhase 3Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNeurologyAug 2027
NCT05067790Nusinersen (BIIB058)Phase 3Spinal Muscular AtrophyNeurologySep 2027
NCT06555419Nusinersen (BIIB058)Phase 1Muscular Atrophy, SpinalNeurologySep 2027
NCT06953583Omaveloxolone (BIIB141)Phase 3Friedreich AtaxiaNeurologyNov 2027
NCT05531565Litifilimab (BIIB059)Phase 2Subacute Cutaneous Lupus ErythematosusImmunologyDec 2027
NCT07722546FelzartamabPhase 2Graves' DiseaseMetabolic and endocrineJan 2028
NCT07219043FelzartamabPhase 2Microvascular InflammationImmunologyFeb 2028
NCT05399888DiranersenPhase 2Mild Cognitive Impairment Due to Alzheimer's DiseaseNeurologyJun 2028
NCT07662148BIIB144Phase 1Healthy VolunteerOtherJun 2028
NCT07444476Salanersen (BIIB115)Phase 3Spinal Muscular AtrophyNeurologyJun 2028
NCT07221669Salanersen (BIIB115)Phase 3Muscular Atrophy, SpinalNeurologyNov 2028
NCT07444450Salanersen (BIIB115)Phase 3Muscular Atrophy, SpinalNeurologyJul 2029
NCT06962800FelzartamabPhase 3Primary Membranous NephropathyGenitourinaryJan 2030
NCT06054893Omaveloxolone (BIIB141)Phase 1Friedreich AtaxiaNeurologyJun 2030
NCT05575011Salanersen (BIIB115)Phase 1Healthy VolunteerNeurologyNov 2031
NCT07855211BIIB147Phase 1Amyotrophic Lateral SclerosisNeurologyJan 2034

From the company's SEC filings

Cash and short-term investments of $1.3bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SMN2 (2) CD38 (1) CLEC4C (1) NFE2L2 (1) SOD1 (1) IFNAR1 (1) IFNAR2 (1) ATXN2 (1)

Companies with the same targets

Novartis Roche Takeda Johnson & Johnson (Janssen) Zhejiang ACEA Pharmaceutical CASI pharmaceuticals Sanofi Celltrion GSK Sinocelltech

Companies built like this

Ionis Pharmaceuticals UCB Biopharma SRL Alnylam Pharmaceuticals Praxis Precision Medicines Sarepta Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.